- From Big Pharma to specialty: why moving closer to the patient changes everythingWorking at a Big Pharma has its benefits, but there are limitations too. SERB Pharmaceuticals’ Thomas Kolaras discusses how moving to a midsize company creates new opportunities for sharpened think…BioSpace · 6d ago↗ source
- Celldex ends skin disease program after failing phase 2 testA phase 2 study of Celldex’s barzolvolimab in a chronic skin disease has missed its primary endpoint, driving the biotech to end development in the indication and raising doubts about an upcoming e…Fierce Biotech · 6d ago↗ source
- AI data becomes sticking point in biopharma dealmakingAs drug hunting gets more complex, where and how data is generated in partnerships between Big Pharmas and AI biotechs is becoming a headache for dealmakers.